-
ASCO doubles the OS of specific TNBC patients with Trop-2 antibody conjugated drug Phase 3 results are positive
Time of Update: 2021-06-10
The latest results in a phase 3 clinical trial in patients with triple negative breast cancer (TNBC).
It has been approved for Phase 3 clinical trials in China to treat metastatic triple-negative breast cancer and advanced urothelial cancer that have received at least 2 lines of previous treatment.
-
There are new discoveries in the prediction of the efficacy of lung cancer immunotherapy; TROP-2
Time of Update: 2021-05-21
*Only for medical professionals to read for reference 1 minute a day, give you professional "talking information" in the tumor circle! (If you need the original text of the literature, you can add th
-
Gilead's Trop-2 antibody conjugate drug gains second indication
Time of Update: 2021-04-18
S. FDA has accelerated the approval of its Trop-2 antibody conjugate drug Trodelvy (sacituzumab govitecan-hziy) to expand its scope of use for the treatment of locally advanced or metastatic urothelium Cancer patients.
-
Express | Gilead's Trop-2 antibody-conjugated drug gains second indication for the treatment of bladder cancer
Time of Update: 2021-04-18
S. FDA has accelerated its approval of its Trop-2 antibody conjugate drug Trodelvy (sacituzumab govitecan-hziy) to expand the scope of use for local treatment Patients with advanced or metastatic urothelial cancer.
-
GUT: Anti-SARS-CoV-2 antibody response weakened in patients with IBD treated with infliximab
Time of Update: 2021-03-30
Nicholas A Kennedy sought to determine whether IBD patients treated with infliximab had attenuated the serological response to SARS-CoV-2 infection.
The serological response to SARS-CoV-2 infection in patients receiving infliximab treatment decreased, and the seroprevalence rate, seroconversion rate, and antibody reactivity decreased.
-
GUT: Anti-SARS-CoV-2 antibody response weakened in patients with IBD treated with infliximab
Time of Update: 2021-03-26
Nicholas A Kennedy sought to determine whether IBD patients treated with infliximab had attenuated the serological response to SARS-CoV-2 infection.
The serological response to SARS-CoV-2 infection in patients receiving infliximab treatment decreased, and the seroprevalence rate, seroconversion rate, and antibody reactivity decreased.
-
Lancet: In the first wave of new coronary pneumonia outbreak, the U.S. SARS-CoV-2 antibody-positive rate was studied.
Time of Update: 2020-10-30
extracted data on age, gender, race, residence, and facility zip codes from anonymous electronic health records, linking patient-level residence data to cumulative, daily cases, deaths, and nasal swab-testing rates per 100,000 population to assess the positive rates for dialysis and new coronary pneumonia virus in the U.S. population.
-
Several important research results focus on new advances in the field of SARS-CoV-2 antibody research!
Time of Update: 2020-07-30
to uncover this secret, researchers from the Duke-NUS School of Medicine and the A-STAR Institute, led by Antonio Bertoletti, studied for the first time the reaction of T cells in patients with COVID-19 recovery to the structural regions of SARS-CoV-2 (nuclear shell protein, NP) and non-structural regions (ORF1 NSP-7 and NSP13), published in the journal Nature.
-
Clinica Chimica Acta: What are the SARS-CoV-2 antibody characteristics of two semi-quantitative
Time of Update: 2020-07-27
!---- In the current COVID-19 pandemic, there is an urgent need for comprehensive performance assessment and clinical efficacy assessment of serological testing to understand the immune system's respo
-
The Endofer of the Ebola outbreak! 2 antibody therapies significantly reduce Ebola infection mortality
Time of Update: 2020-06-07
mAb114 is a monoclonal antibody that originated in the 1995 Ebola outbreak in Kikwete, Democratic Republic of the Congo In that outbreak, survivors remained anti-Ebola antibodies for up to 11 years af
-
/Liu Bingfeng collaborated to reveal infection Omicron BA. 2. Antibody reaction and cross-neutralization after 2
Time of Update: 2023-02-02
Consistent with previous reports on Omicron's enhanced immune evasion capacity, early antibody responses favored the ancestral SARS-CoV-2 strain In addition, the booster dose of the vaccine (third dose) resulted The IgG titer was significantly increased, not only significantly binding to BA.
-
Nebulized inhaled mRNA-encoded membrane-localized antibodies for SARS-CoV-2 infection protection in hamsters
Time of Update: 2023-01-06
Hogan of the University of Georgia in October 2022 Infection", the article developed a novel nebulized mRNA code to neutralize the mAb and validated it in a hamster infection model, confirming that the mAb can be effectively used in the prevention and treatment of SARS-CoV-2.
-
Nature sub-issue 1 published 2 articles: The new oncolytic virus is equipped with dual antibodies
Time of Update: 2023-01-06
Official website of each company——List of recent popular events——November 23, Key Elements of Quality Control for mRNA VaccinesNovember 19, 2022 / eMedClub News / -- November 17, 2022, Nature Cancer In an article titled "An armed oncolytic virus for GBM destruction," an oncolytic herpes simplex virus (oHSV) that carries a bispecific EGFR-CCL5 antibody fusion protein that activates innate and adaptive anti-tumor immune responses has shown extremely high efficacy in preclinical models of glioblastoma (GBM).
-
Nature sub-issue 1 published 2 articles: The new oncolytic virus is equipped with dual antibodies
Time of Update: 2023-01-06
Official website of each company——List of recent popular events——November 23, Key Elements of Quality Control for mRNA VaccinesNovember 19, 2022 / eMedClub News / -- November 17, 2022, Nature Cancer In an article titled "An armed oncolytic virus for GBM destruction," an oncolytic herpes simplex virus (oHSV) that carries a bispecific EGFR-CCL5 antibody fusion protein that activates innate and adaptive anti-tumor immune responses has shown extremely high efficacy in preclinical models of glioblastoma (GBM).
-
Nebulized inhaled mRNA-encoded membrane-localized antibodies for SARS-CoV-2 infection protection in hamsters
Time of Update: 2023-01-06
Hogan of the University of Georgia in October 2022 Infection", the article developed a novel nebulized mRNA code to neutralize the mAb and validated it in a hamster infection model, confirming that the mAb can be effectively used in the prevention and treatment of SARS-CoV-2.
